AVDL
AVADEL PHARMACEUTICALS PLC
Key Financials
Operating Income
$-42399000
↑ 69.2%
Gross Profit
$153.8M
↑ 467.3%
Net Income
$-48832000
↑ 69.5%
Revenue
$169.1M
↑ 504.8%
EPS (Diluted)
$-0.51
↑ 74.5%
Shareholders' Equity
$73.8M
↓ 15.8%
Total Liabilities
$90.4M
↑ 17.4%
Cash & Equivalents
$51.4M
↑ 64.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 15-12G | 2/23/2026 | View on SEC |
| 4 | 2/18/2026 | View on SEC |
| 3 | 2/18/2026 | View on SEC |
| SCHEDULE 13G/A | 2/17/2026 | View on SEC |
| SCHEDULE 13G/A | 2/17/2026 | View on SEC |
| EFFECT | 2/13/2026 | View on SEC |
| EFFECT | 2/13/2026 | View on SEC |
| EFFECT | 2/13/2026 | View on SEC |
| EFFECT | 2/13/2026 | View on SEC |
| 4 | 2/12/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AVDL |
| Company Name | AVADEL PHARMACEUTICALS PLC |
| CIK | 1012477 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | 636-449-1830 |